• LAST PRICE
    2.8700
  • TODAY'S CHANGE (%)
    Trending Up0.0900 (3.2374%)
  • Bid / Lots
    2.7500/ 1
  • Ask / Lots
    3.5500/ 19
  • Open / Previous Close
    2.9900 / 2.7800
  • Day Range
    Low 2.8700
    High 3.0850
  • 52 Week Range
    Low 1.6200
    High 4.0500
  • Volume
    3,912
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.78
TimeVolumeANEB
09:32 ET10032.99
03:23 ET18002.995
03:57 ET3243.08
03:59 ET3102.87
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesANEB
Anebulo Pharmaceuticals Inc
74.4M
-7.0x
---
United StatesPASG
Passage Bio Inc
75.1M
-0.7x
---
United StatesELYM
Eliem Therapeutics Inc
75.5M
-1.9x
---
United StatesCKPT
Checkpoint Therapeutics Inc
73.2M
-0.7x
---
United StatesNVNO
enVVeno Medical Corp
72.4M
-2.8x
---
United StatesIMMX
Immix Biopharma Inc
77.2M
-3.3x
---
As of 2024-03-29

Company Information

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system.

Contact Information

Headquarters
Jfl Capital Management 1017 Rr 620 S, Suite 107LAKEWAY, TX, United States 78734
Phone
512-598-0931
Fax
---

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$74.4M
Revenue (TTM)
$0.00
Shares Outstanding
25.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.41
Book Value
$0.41
P/E Ratio
-7.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.